SCHEMBL597167

SCHEMBL597167

CC[C@@](O)(c1ccccc1)N1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.52
CYP2D6 P10635 4/20 0.45
CHRM2 P08172 3/20 0.45
CHRM1 P11229 3/20 0.45
HTR1A P08908 2/20 0.45
OPRM1 P35372 2/20 0.45
KCNH2 Q12809 2/20 0.45
LMNA P02545 2/20 0.45
CHRM4 P08173 2/20 0.42
CHRM5 P08912 2/20 0.42
CHRM3 P20309 2/20 0.42
KDM4E B2RXH2 2/20 0.42
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
HTR2A P28223 1/20 0.42
DRD3 P35462 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
SCN3A Q9NY46 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8013935 1.00 CYP2B6 (0.52) CYP2B6CYP2D6CHRM2CHRM1HTR1A
Hydrochloric Acid SCHEMBL8017738 0.98 CYP2B6 (0.50) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL7547849 0.98 CYP2B6 (0.55) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL4541997 0.84 KCNA5 (0.48) OPRM1LMNAKMT2AMEN1ALDH1A1
SCHEMBL9816209 0.84 CHRM2 (0.48) CYP2D6CHRM2CHRM1HTR1AOPRM1
SCHEMBL9366900 0.79 CYP2B6 (0.49) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL5305394 0.77 CYP2B6 (0.55) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL14354381 0.76 CYP2B6 (0.39) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL5302731 0.76 CYP2B6 (0.58) CYP2B6CYP2D6CHRM2CHRM1HTR1A
SCHEMBL2707429 0.76 CYP2B6 (0.58) CYP2B6CYP2D6CHRM2CHRM1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2417096-B1 Process for the synthesis of a propargylic alcohol LONZA AG (CH) 2013-01-16 EP disclosed
US-8283502-B2 Autocatalytic process for the synthesis of chiral propargylic alcohols LONZA LTD. (CH) 2012-10-09 US disclosed
US-8115032-B2 Process for the synthesis of a propargylic alcohol LONZA LTD. (CH) 2012-02-14 US disclosed
US-20110172464-A1 PROCESS FOR THE SYNTHESIS OF A PROPARGYLIC ALCOHOL LONZA LTD. (CH) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172464-A1 PROCESS FOR THE SYNTHESIS OF A PROPARGYLIC ALCOHOL ADH1A, ADH1C, ADH5 CYP2B6 59/4885CYP2D6 128/4885CHRM2 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.